BioStem Technologies ((BSEM)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BioStem Technologies is conducting a clinical trial titled ‘A Prospective, Multicenter, Randomized, Controlled Trial of Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AC.’ The study aims to evaluate the safety and efficacy of BioREtain® Amnion Chorion (BR-AC) in treating diabetic foot ulcers, comparing it to standard care alone. This trial is significant as it addresses a common complication of diabetes, potentially offering a more effective treatment option.
The intervention being tested is BR-AC, a human placental allograft designed to promote healing in non-healing diabetic foot ulcers. It is applied in conjunction with standard care, which includes debridement, wound cleansing, and appropriate dressings.
The study is interventional with a randomized, parallel assignment. It employs single masking to reduce bias, with an independent reviewer assessing wound closure. The primary purpose is treatment, focusing on the efficacy of BR-AC in healing diabetic foot ulcers.
The study began on September 3, 2024, with primary completion expected by June 23, 2025. The last update was submitted on June 23, 2025, indicating ongoing progress and data collection.
This study update could positively impact BioStem Technologies’ stock performance by showcasing potential advancements in diabetic foot ulcer treatment. Investors might view this as a promising development, especially in comparison to competitors lacking similar innovations.
The study is ongoing, with further details available on the ClinicalTrials portal.